Still a relatively slow start to the week but there is still some interesting news. The sector has certainly bounced from the lows it experienced after the election, but we might actually be back into a range bound sector. It looked like we had broken out but now I am not so sure. This could […]
November 26th Biotech Update
A nice recovery for the sector and so it is not surprising that we see a little pause. Perhaps we can continue the momentum the rest of the week but we are approaching a holiday and so I expect volumes to slow down and the momentum of this initial bounce to pause. This is not […]
November 25th Biotech Update
I suspect that the sector could be on pace to a nice recovery this week. Vivek comments this weekend and the FDA commissioner nominee may has allayed some concerns about the incoming administration and their relationship with the sector. I am not completely convinced about anything at this point but what I see it is […]
November 20th Biotech Update
We got the bounce that I was sort of expecting and I would not be surprised if it continued. We are right at pretty strong support (or what I thought should have been pretty strong support). My base case is that we should expect this bounce to continue but I am still not 100% sure […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
